The team presented the confirmatory additional endpoints of the Ruby trial which showed with the addition of dostarlimab immunotherapy added to chemotherapy for patients with advanced or recurrent endometrial cancer, there is a 71% improvement in progression-free survival or death for the biomarker-positive population and a 34% improvement in the overall population. Although we are still following many patients on the trial, it looks like overall survival is improved with an acceptable safety profile.
This has become another tool we have in our armamentarium because our big goal has been moving this to frontline therapy,”
Matthew Powell, MD, in an interview with Targeted Oncology™.